
AERI
Healthcare · Drug Manufacturers - Specialty & Generic · $753.6M market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2022
EPS trend, 90 days to now · 0.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 3, 2022 | After the close | -0.44 | -0.27 | +38.6% |
| Aug 4, 2022 | After the close | -0.56 | -0.32 | +42.9% |
| May 5, 2022 | After the close | -0.65 | -0.66 | -1.5% |
| Feb 24, 2022 | After the close | -0.67 | 1.09 | +262.7% |
| Nov 4, 2021 | After the close | -0.62 | -0.72 | -16.1% |
| Aug 4, 2021 | After the close | -0.64 | -0.67 | -4.7% |
| May 5, 2021 | After the close | -0.68 | -0.72 | -5.9% |
| Feb 25, 2021 | After the close | -0.76 | -0.79 | -3.9% |
| Nov 5, 2020 | After the close | -0.82 | -0.65 | +20.7% |
| Aug 6, 2020 | After the close | -0.80 | -0.83 | -3.8% |
| May 6, 2020 | After the close | -0.77 | -0.83 | -7.8% |
| Feb 20, 2020 | After the close | -0.77 | -0.96 | -24.7% |
| Nov 6, 2019 | After the close | -0.80 | -0.86 |
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular…
| -7.5% |
| Aug 7, 2019 | After the close | -0.86 | -0.80 | +7.0% |
| May 7, 2019 | After the close | -0.93 | -0.78 | +16.1% |
| Feb 25, 2019 | After the close | -0.87 | -0.92 | -5.7% |
| Nov 6, 2018 | After the close | -1.38 | -1.73 | -25.4% |
| Aug 8, 2018 | After the close | -0.98 | -1.14 | -16.3% |
| May 8, 2018 | After the close | -0.87 | -0.83 | +4.6% |
| Feb 28, 2018 | After the close | -1.21 | -1.38 | -14.0% |